Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C

Antiviral Research

Volumn 113, Issue , 2015, Pages 71-78

  Howe, Anita Y M ^a   Long, Jianmin ^a   Nickle, David ^a,b   Barnard, Richard ^a   Thompson, Seth ^a   Howe, John ^a   Alves, Katia ^a   Wahl, Janice ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Merck Research Laboratories   (United States)

Author keywords

Boceprevir; Hepatitis C; Relapse; Resistance

Indexed keywords

BOCEPREVIR; VIRUS RNA; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PROLINE;

ARTICLE; DRUG TREATMENT FAILURE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; RELAPSE; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS MUTANT; WILD TYPE; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MALE; MUTATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RECURRENT DISEASE; TREATMENT FAILURE; VIROLOGY;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MUTATION; PHENOTYPE; PROLINE; RECURRENCE; TREATMENT FAILURE;

EID: 84911919899     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.10.010     Document Type: Article

References (20)

1. Bacon, B., Gordon, S.C., Lawitz, E., et al., 2011. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207-1217.
2. Barnard, R.J., Howe, J.A., Ogert, R.A., et al., 2013. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology 444, 329-336.
3. Edgar, R.C., 2004. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 5, 113.
4. Guindon, S., Dufayard, J.F., Lefort, V., Anisimova, M., Hordijk, W., Gascuel, O., 2010. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst. Biol. 59, 307-321.
5. Harrington, P.R., Zeng, W., Naeger, L.K., 2012. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 55, 1048-1057.
6. Kwo, P.Y., Lawitz, E.J., McCone, J., et al., 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376, 705-716.
7. Lenz, O., Verbinnen, T., Lin, T.I., et al., 2010. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob. Agents Chemother. 54, 1878-1887.
8. Manns, M.P., Pockros, P.J., Norkrans, G., et al., 2013. Long-term clearance of hepatitis C virus following interferon alpha-2b or peginterferon alpha-2b, alone or in combination with ribavirin. J. Viral Hepat. 20, 524-529.
9. Marcellin, P., Boyer, N., Gervais, A., et al., 1997. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann. Intern. Med. 127, 875-881.
10. Ogert, R.A., Howe, J.A., Vierling, J.M., et al., 2013. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-alpha2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. Antiviral Ther. 18, 387-397.
11. Poordad, F., Bronowicki, J.P., Gordon, S.C., et al., 2012. Factors that predict response of patients with HCV Infection to boceprevir. Gastroenterology 143, 608-618.
12. Poordad, F., McCone, J., Bacon, B.R., et al., 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195-1206.
13. Rutter, K., Hofer, H., Beinhardt, S., et al., 2013. Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting antiviral. Aliment. Pharmacol. Ther. 38, 118-123.
14. Schiff, E., Poordad, F., Jacobson, I., et al., 2008. Boceprevir (b) combination therapy in null responders (NR): response dependent on interferon responsiveness. J. Hepatol. 48 (Suppl. 2), S46.
15. Shimakami, T., Welsch, C., Yamane, D., et al., 2011. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 140, 667-675.
16. Sullivan, J.C., De Meyer, S., Bartels, D.J., et al., 2013. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin. Infect. Dis. 57, 221-229.
17. Susser, S., Welsch, C., Wang, Y., et al., 2009. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50, 1709-1718.
18. Swain, M.G., Lai, M.Y., Shiffman, M.L., et al., 2010. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139, 1593-1601.
19. Tong, X., Bogen, S., Chase, R., et al., 2008. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res. 77, 177-185.
20. Tong, X., Chase, R., Skelton, A., Chen, T., Wright-Minogue, J., Malcolm, B.A., 2006. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res. 70, 28-38.